Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H25O5S.Na |
| Molecular Weight | 376.443 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]12CC[C@H](OS([O-])(=O)=O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]
InChI
InChIKey=JHAJPDCWGNULRU-OGVPJBRJSA-M
InChI=1S/C18H26O5S.Na/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22;/h10,13-17H,2-9H2,1H3,(H,20,21,22);/q;+1/p-1/t13-,14+,15+,16-,17-,18-;/m0./s1
DescriptionCurator's Comment: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Curator's Comment: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a semisynthetic anabolic-androgenic steroid derived from testosterone. Nandrolone is used in the form of a variety of long-acting prodrug esters for intramuscular injection, the most common of which are nandrolone decanoate. Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testis. Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. Synthetic version of nandrolone was developed in 1950. But nandrolone for sale appeared later only in 1962 in the form of decanoate under the trade name Deca-Durabolin (Organon company).
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL1871 |
|||
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NANDROLONE DECANOATE Approved UseNandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. Launch Date2010 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
36.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
219.9 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sport nutritional supplements: quality and doping controls. | 2001 |
|
| [The combined effect of retabolile and support loads on the post-traumatic reparation process in suspended rat muscles]. | 2001 |
|
| Consequence of boar edible tissue consumption on urinary profiles of nandrolone metabolites. II. Identification and quantification of 19-norsteroids responsible for 19-norandrosterone and 19-noretiocholanolone excretion in human urine. | 2001 |
|
| Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. | 2001 Apr |
|
| Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat and Valette. | 2001 Apr |
|
| Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. | 2001 Aug 17 |
|
| Advances in male hormonal contraception. | 2001 Dec |
|
| Urinary nandrolone metabolites of endogenous origin in man: a confirmation by output regulation under human chorionic gonadotropin stimulation. | 2001 Jan |
|
| The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. | 2001 Jan |
|
| Detection and determination of anabolic steroids in nutritional supplements. | 2001 Jul |
|
| Novel amino acid substitutional mutation, tyrosine-739-aspartic acid, in the androgen receptor gene in complete androgen insensitivity syndrome. | 2001 Jun |
|
| Anabolic steroids increase exercise tolerance. | 2001 Jun |
|
| [Treatment of endometriosis with dienogest: preliminary report]. | 2001 May |
|
| Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. | 2001 May 30 |
|
| Aggression in male rats receiving anabolic androgenic steroids: effects of social and environmental provocation. | 2001 Nov |
|
| Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. | 2001 Nov-Dec |
|
| Drugs and food supplements in sports. The nandrolone lessons. | 2001 Oct |
|
| [Urinary nandrolone metabolites in antidoping control]. | 2001 Sep |
|
| [New gestagens--advantages and disadvantages]. | 2001 Sep |
|
| Estimation of hormone replacement therapy influence on serum galanin level in postmenopausal women. | 2001 Sep |
|
| Role of androgens in female genital sexual arousal: receptor expression, structure, and function. | 2002 Apr |
|
| The popliteal-artery entrapment syndrome in a patient using anabolic steroids. | 2002 Apr 18 |
|
| Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. | 2002 Aug |
|
| Metabolic effects of nandrolone decanoate and resistance training in men with HIV. | 2002 Dec |
|
| Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. | 2002 Feb |
|
| Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. | 2002 Jan |
|
| Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. | 2002 Jun 15 |
|
| Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. | 2002 Mar |
|
| The human ovarian surface epithelium is an androgen responsive tissue. | 2002 Mar 18 |
|
| Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective. | 2002 Nov 15 |
|
| Urine nandrolone metabolites: false positive doping test? | 2002 Oct |
|
| Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. | 2002 Oct 25 |
|
| Successful DNA typing of a urine sample in a doping control case using human mitochondrial DNA analysis. | 2002 Sep |
|
| Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. | 2002 Sep |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2360
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
60672-82-4
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
100000085710
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
SUB03387MIG
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
23670636
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
W945A5Q7XN
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
Nandrolone sodium sulfate
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
262-368-0
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY | |||
|
C95973
Created by
admin on Sat Dec 16 05:54:41 GMT 2023 , Edited by admin on Sat Dec 16 05:54:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
